Scarica l'app Stockscreener
0.8221
0.69%
0.0056
Dopo l'orario di chiusura:
.83
0.0079
+0.96%
Precedente Chiudi:
$0.8165
Aprire:
$0.8348
Volume 24 ore:
7.12M
Relative Volume:
1.57
Capitalizzazione di mercato:
$242.32M
Reddito:
$55.87M
Utile/perdita netta:
$-77.60M
Rapporto P/E:
-2.3047
EPS:
-0.3567
Flusso di cassa netto:
$-79.46M
1 W Prestazione:
-12.00%
1M Prestazione:
+2.25%
6M Prestazione:
-35.77%
1 anno Prestazione:
-32.61%
Intervallo 1D:
$0.77
$0.8442
Intervallo di 1 settimana:
$0.77
$1.01
Portata 52W:
$0.5277
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Nome
Invivyd Inc
Settore
Industria
Telefono
(781) 819-0080
Indirizzo
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.8221 | 275.36M | 55.87M | -77.60M | -79.46M | -0.3567 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-22 | Iniziato | BTIG Research | Buy |
| 2025-11-25 | Downgrade | D. Boral Capital | Buy → Hold |
| 2025-10-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-26 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Invivyd Inc Borsa (IVVD) Ultime notizie
Invivyd Inc (IVVD-Q) Stock Price and News - The Globe and Mail
BTIG Sticks to Its Buy Rating for Invivyd (IVVD) - The Globe and Mail
Invivyd,Vyd2311 Combined With Mrna Covid-1 - Moomoo
Invivyd’s Covid-directed mAb hits Phase III safety goals - Yahoo Finance
H.C. Wainwright reiterates Invivyd stock rating on trial data By Investing.com - Investing.com Nigeria
Invivyd stock reports positive LIBERTY safety data - AD HOC NEWS
Why Is Invivyd Stock Trading Lower Today?Invivyd (NASDAQ:IVVD) - Benzinga
Invivyd drops after delaying late-stage trial data for COVID therapy - TradingView
Ascletis challenges psoriasis field with pill; Invivyd plans Covid filing - Endpoints News
Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission - Yahoo Finance
Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory SubmissionSlideshow (NASDAQ:IVVD) 2026-09-29 - Seeking Alpha
Invivyd Phase 3 COVID Antibody Trial Shows Superior Safety - TipRanks
Form 8K Invivyd Inc For: 29 September By Investing.com - Investing.com Nigeria
A 210-person study compared Invivyd (IVVD)'s COVID-19 antibody with a vaccine. Event rates differed. - Stock Titan
In a trial, 56.5% had an adverse event, injection reaction or allergy with Invivyd's COVID antibody, versus 91.4% with an mRNA vaccine. - Stock Titan
Invivyd Inc (IVVD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Invivyd stock falls 8 percent as earnings miss estimates - AD HOC NEWS
Invivyd, Inc.(NasdaqGM: IVVD) added to S&P Global BMI Index - marketscreener.com
3 Small-Cap Biotechs With Binary Catalysts on the Calendar - marketbeat.com
INVIVYD INC (IVVD) Stock Chart - ChartMill
IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730% - Stocktwits
Invivyd to Participate in Upcoming September Investor Conferences - manilatimes.net
Invivyd management will join two live webcast chats in September - Stock Titan
Invivyd stock holds steady as investors watch recent trial progress - ad-hoc-news.de
IVVD News | INVIVYD INC (NASDAQ:IVVD) - ChartMill
Invivyd Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout - Fierce Biotech
Invivyd names chairman Marc Elia as chief executive, ahead of pivotal VYD2311 data - The Pharma Letter
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Invivyd stock falls as investors await VYD2311 data - ad-hoc-news.de
Six new hires receive rights to buy 255,000 Invivyd shares - Stock Titan
Director at Invivyd (IVVD) granted 100K stock options - Stock Titan
No Invivyd (NASDAQ: IVVD) shares listed in company director's ownership filing - Stock Titan
Invivyd appoints Marc Elia CEO amid board reshuffle - The Globe and Mail
New multi-million-share option grant for Invivyd (IVVD) CEO - stocktitan.net
Invivyd, Inc. Announces Board Appointments - marketscreener.com
New Haven COVID drugmaker names new CEO ahead of key trial results - Hartford Business Journal
Invivyd Names Chairman Marc Elia as CEO - marketscreener.com
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY - The Manila Times
Invivyd Names Marc Elia CEO, Adds New Independent Director as VYD2311 Phase 3 Studies Near Completion - Quiver Quantitative
Invivyd (IVVD) gives its new CEO rich equity and a potential 0.5%–1.5% payout on any sale worth at least $5B, as Phase 3 COVID antibody data near. - Stock Titan
Cantor Fitzgerald reiterates Invivyd stock rating on COVID trends By Investing.com - Investing.com UK
Cantor Fitzgerald reiterates Invivyd stock rating on COVID trends - Investing.com
Invivyd (IVVD) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison in Latest Trading; Share Response - careplusvn.com
IVVD|Invivyd Inc|Price:0.997|Chg%:+0.046 - TradingKey
Invivyd (IVVD) Results Check: Profit Per Share Falls Below Its Benchmark on the Day; Price Move: The Stock Ends Up 2.65%Earnings Sentiment Score - vinanet.vn
Invivyd Stock (IVVD) Opinions on Upcoming Phase 3 Results - Moomoo
Invivyd (IVVD) Q1 2026 Results: The EPS Result Is Below Expectation; Closing Reaction: Shares Finish 10.53% Higher for the Current SessionEPS Revision Trend - vinanet.vn
FY2026 EPS Estimates for Invivyd Increased by HC Wainwright - MarketBeat
Invivyd CSO Robert Allen III sells $29,295 in stock By Investing.com - Investing.com South Africa
Invivyd chief legal officer Jill Andersen sells $52,780 in shares By Investing.com - Investing.com Australia
Invivyd Inc Azioni (IVVD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Invivyd Inc Azioni (IVVD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lee Timothy Edward | Chief Commercial Officer |
Aug 18 '26 |
Sale |
0.84 |
18,425 |
15,530 |
178,937 |
| Green Julie | Chief Human Resources Officer |
Aug 17 '26 |
Sale |
0.72 |
22,355 |
16,140 |
187,362 |
| Green Julie | Chief Human Resources Officer |
Aug 18 '26 |
Sale |
0.84 |
18,425 |
15,530 |
168,937 |
| Duke William E. | Chief Financial Officer |
Aug 17 '26 |
Sale |
0.72 |
22,355 |
16,140 |
187,362 |
| Duke William E. | Chief Financial Officer |
Aug 18 '26 |
Sale |
0.84 |
18,425 |
15,530 |
168,937 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 17 '26 |
Sale |
0.72 |
37,256 |
26,899 |
314,480 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 18 '26 |
Sale |
0.84 |
30,706 |
25,882 |
283,774 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 17 '26 |
Sale |
0.72 |
20,679 |
14,930 |
195,808 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 18 '26 |
Sale |
0.84 |
17,043 |
14,366 |
178,765 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):